Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Closes $57M Financing; Will Use Funds to Commercialize Verigene, Biobarcode Systems

NEW YORK, May 16 (GenomeWeb News) - Nanosphere said today that it has closed $57 million in a Series D financing led by Bain Capital.

 

The company will use the funding to commercialize its Verigene System, a genomic testing platform that Nanosphere said eliminates the need for PCR.

 

Nanosphere will also use the proceeds to further development and commercialization of its Biobarcode technology for detecting proteins and nucleic acids.

 

Other investors in the round include Allen & Company and founding investor Lurie Investments.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.